Reliv Strengthens LunaRich Patent

View Reliv International Profile

8/20/2015

CHESTERFIELD, MO, Aug 18, 2015 -- Reliv International, Inc., a maker of nutritional supplements that promote optimal health, today announced that the U.S. Patent and Trademark Office has issued an expanded patent for LunaRich, Reliv's exclusive nutritional ingredient. The updated patent further protects LunaRich technology as it relates to the soy peptide lunasin's mechanism of action for lowering LDL cholesterol levels.

Lunasin is a naturally occurring peptide scientists have identified as the key to many of soy's documented health benefits. LunaRich optimizes bioactive lunasin more than any other source available today.

"Novel ingredients like LunaRich that boast a spectrum of nutritional technologies often require continual patent updates," said Dr. Carl W. Hastings, Reliv vice chairman and chief scientific officer. "Reliv is committed to securing the strongest patent portfolio possible for this remarkable nutritional ingredient."

Reliv also holds a composition of matter patent related to LunaRich's superior ability to deliver bioactive lunasin to the body. Nine Reliv products have also been issued patents, with three of those having since reached the 20-year limit and expired.

"Protecting an asset like LunaRich is a process," said Ryan Montgomery, Reliv president. "We expect to receive continued enhancements to current patents, and we have additional unique patents pending. LunaRich puts Reliv and our products on a higher level in the industry, and we want to guarantee that the only place consumers can purchase LunaRich is through independent Reliv distributors."